DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Eris Lifesciences Limited — Outcome of Board Meeting

NSE 50 min ago·26 Oct 2026, 8:19 am

Eris Lifesciences

Eris Lifesciences has informed the stock exchanges that its board has approved the financial results for the quarter and nine months ended September 30, 2026. This submission marks a routine regulatory requirement for listed companies to disclose their financial performance to the public.

For investors, this update provides a crucial data point to evaluate the company's operational health and financial trajectory. It allows stakeholders to assess the company's growth momentum and operational efficiency ahead of the broader market's expectations.

Investors should focus on the key performance indicators within the results, such as revenue growth and profit margins. Monitoring the management's commentary on future outlook will be essential to gauge the company's strategic direction and potential market positioning.